Strategy and novel technology for treatment of Ebola virus disease: Research advances / 国际药学研究杂志

Ebola virus is a highly virulent pathogen causing severe hemorrhagic fever with a high fatality rate in humans. Although safe and effective therapeutics and treatment strategies or other medicinal agents in post-exposure therapeutics for the prevention of Ebola hemorrhagic are currently unavailable, a significant effort has been put forth to identify several promising candidates for post-exposure therapeutics and treatment of Ebola hemorrhagic fever. These potential strategies and novel technology include monoclonal antibody cocktail, polymerase inhibitors and lipid nanoparticle/small interfering RNA. This article summarizes recent advances in therapeutics and treatment strategies and novel technology in Ebola virus post-infection in small animals and non-human primates.

Single-color Multitarget Flow Cytometry Using Monoclonal Antibodies Labeled with Different Intensities of the Same Fluorochrome

BACKGROUND: We developed a single-color multitarget flow cytometry (SM-FC) assay, a single-tube assay with graded mean fluorescence intensities (MFIs). We evaluated the repeatability of SM-FC, and its correlation with multicolor flow cytometry (MFC), to assess its application as a routine FC assay. METHODS: We selected CD19, CD3, CD4, and CD8 as antigen targets to analyze a lymphocyte subset. MFIs were graded by adjusting monoclonal antibody (mAb) volumes to detect several cell populations. Dimly labeled mAb was prepared by decreasing mAb volume and the optimum diluted volume was determined by serial dilution. SM-FC repeatability was analyzed 10 times in 2 normal controls. The correlation between SM-FC and MFC was evaluated in 20 normal and 23 patient samples. RESULTS: CV values (0.8-5.0% and 1.3-4.1% in samples 1 and 2, respectively) acquired by SM-FC with CD3-fluorescein alpha-isothyocyanate (FITC)dim+CD4-FITCbright and with CD19-FITCdim+CD3-FITCbright showed good repeatability, comparable to that acquired by MFC (1.6-3.7% and 1.0-4.8% in samples 1 and 2, respectively). Excellent correlation was observed between the 2 methods in the 20 normal samples (B cells, T cells, non-Thelper cells, and Thelper cells; r2=0.87, 0.97, 0.97, and 0.98, respectively; P or =0.98, 0.99, 0.99, and 0.99, respectively; P<0.05). CONCLUSIONS: The multicolor, single-tube SM-FC technique is a potential alternative tool for identifying a lymphocyte subset.